TNSN97085A1 - Substitution oxybuterique des acides comme inhibiteurs de la matrice metalloprotease - Google Patents

Substitution oxybuterique des acides comme inhibiteurs de la matrice metalloprotease

Info

Publication number
TNSN97085A1
TNSN97085A1 TNTNSN97085A TNSN97085A TNSN97085A1 TN SN97085 A1 TNSN97085 A1 TN SN97085A1 TN TNSN97085 A TNTNSN97085 A TN TNSN97085A TN SN97085 A TNSN97085 A TN SN97085A TN SN97085 A1 TNSN97085 A1 TN SN97085A1
Authority
TN
Tunisia
Prior art keywords
oxybuteric
substitution
acids
metalloprotease
metalloprotease matrix
Prior art date
Application number
TNTNSN97085A
Other languages
English (en)
French (fr)
Inventor
r dixon Brian
Chen Jinshan
Van Zandt Michael
r brittelli David
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of TNSN97085A1 publication Critical patent/TNSN97085A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
TNTNSN97085A 1996-05-15 1997-05-09 Substitution oxybuterique des acides comme inhibiteurs de la matrice metalloprotease TNSN97085A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64838496A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
TNSN97085A1 true TNSN97085A1 (fr) 2005-03-15

Family

ID=24600568

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN97085A TNSN97085A1 (fr) 1996-05-15 1997-05-09 Substitution oxybuterique des acides comme inhibiteurs de la matrice metalloprotease

Country Status (18)

Country Link
EP (1) EP0912487A1 (zh)
JP (1) JP3417951B2 (zh)
CN (1) CN1163466C (zh)
AR (1) AR007096A1 (zh)
AU (1) AU727648B2 (zh)
CA (1) CA2253869C (zh)
CO (1) CO4990925A1 (zh)
HR (1) HRP970246B1 (zh)
ID (1) ID20291A (zh)
MY (1) MY132470A (zh)
PA (1) PA8429401A1 (zh)
PE (1) PE65998A1 (zh)
SV (1) SV1997000034A (zh)
TN (1) TNSN97085A1 (zh)
TW (1) TW467892B (zh)
WO (1) WO1997043238A1 (zh)
YU (1) YU18797A (zh)
ZA (1) ZA974032B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
JP5263548B2 (ja) * 2007-08-15 2013-08-14 杏林製薬株式会社 イブジラストを有効成分とする脳動脈瘤の予防、形成抑制又は治療剤
CA2944614A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
EP3126339A1 (de) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
JP2017511319A (ja) 2014-04-03 2017-04-20 バイエル ファーマ アクチエンゲゼルシャフト キラル２，５−ジ置換されたシクロペンタンカルボン酸誘導体およびそれの使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970700652A (ko) * 1994-01-22 1997-02-12 포올 리틀우드 금속단백질 분해효소 억제제

Also Published As

Publication number Publication date
ZA974032B (en) 1998-02-19
WO1997043238A1 (en) 1997-11-20
MY132470A (en) 2007-10-31
CN1225622A (zh) 1999-08-11
AU3121997A (en) 1997-12-05
JP3417951B2 (ja) 2003-06-16
AR007096A1 (es) 1999-10-13
SV1997000034A (es) 1999-07-05
CA2253869C (en) 2003-04-22
PA8429401A1 (es) 2000-05-24
CA2253869A1 (en) 1997-11-20
CN1163466C (zh) 2004-08-25
AU727648B2 (en) 2000-12-21
TW467892B (en) 2001-12-11
CO4990925A1 (es) 2000-12-26
EP0912487A1 (en) 1999-05-06
PE65998A1 (es) 1998-10-20
ID20291A (id) 1998-11-19
HRP970246A2 (en) 1998-04-30
YU18797A (en) 1999-11-22
JPH11509870A (ja) 1999-08-31
HRP970246B1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
EA200100874A1 (ru) Полиморфные кристаллические формы целекоксиба
ATE208397T1 (de) Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe
AU3249295A (en) Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
WO2002046170A8 (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
CA2260016A1 (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
NL300175I1 (nl) Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2.
BR9709501A (pt) Composto, composição farmacêutica , e, processos para tratar ou prevenir a esquizofrrenia e para sintetizar um composto
CA2301742A1 (en) 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
TNSN97085A1 (fr) Substitution oxybuterique des acides comme inhibiteurs de la matrice metalloprotease
DE69533194D1 (de) PYRAZOLO(3,4-g)CHINOXALINE ALS PDGF-REZEPTOR PROTEIN TYROSIN-KINASE INHIBITOREN
CA2254731A1 (en) Inhibition of matrix metalloproteases by 2-substituted-4-(4-substitutedphenyl)-4-oxobutyric acids
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
ATE235468T1 (de) Plättchenaggregationsinhibitoren
CA2211320A1 (en) 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
DE69614392D1 (en) Thrombin inhibitor
Miller et al. Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocket
WO2001003688A3 (en) Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds
TNSN97082A1 (fr) Inhibition des matrices metalloproteases par la substitution des composes phenetyles
NZ287551A (en) N-hydroxyureas that inhibit the 5-lipoxygenase enzyme as anti-inflammatory agents
TNSN97081A1 (fr) Inhibition des matrices metalloproteinases par 2- (w-aroylkyl) -4-biaryl-4-des acides oxubutyriques
HUP0301010A2 (hu) A koleszteril-észter és a viaszészter szintézisét egyaránt gátló vegyületek faggyúmirigy-betegségek kezeléséhez és ezeket tartalmazó gyógyszerkészítmények
TNSN97084A1 (fr) Biaryl acetylenes comme inhibiteurs des matrices metalloproteinases
PL313037A1 (en) Phenoxphenylocyclopententenylohydroxyureas